Blinatumomab Maintenance After Allo-HSCT

Clinical trial NCT06438796 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06438796
Sponsor: Ruijin Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High Risk Acute Lymphoblastic Leukemia

Start date: 2024-07-01
Primary completion: 2026-07-01
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.